# Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

> **NCT06650488** · PHASE4 · RECRUITING · sponsor: **Todd C. Lee MD MPH FIDSA** · enrollment: 300 (estimated)

## Conditions studied

- Staphylococcus Aureus Endocarditis
- Staphylococcus Aureus Septicemia
- Staphylococcus Aureus Bloodstream Infection

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT06650488
- **Lead sponsor:** Todd C. Lee MD MPH FIDSA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650488, "Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT06650488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*